Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00316030 · ClinicalTrials.gov registry record · Phase 1

Study of Bexarotene in Patients With Acute Myeloid Leukemia

A Phase 1 study of Acute Myeloid Leukemia and AML, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
Phase 1
Development phase
54
Enrollment target
1
Study location

NCT00316030 is a Phase 1 study of Acute Myeloid Leukemia and AML that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 54 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00316030, a Phase 1 study of Acute Myeloid Leukemia and AML, has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
Phase 1
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

Bexarotene may be useful in the treatment of Acute Myeloid Leukemia (AML). This is the first study on the use of bexarotene to treat patients with AML. The main purpose of this study is to establish the proper dose of bexarotene when used to treat AML. The side effect profile of bexarotene in patients with AML will also be explored.

Conditions Studied

Acute Myeloid Leukemia AML

Interventions

  • DRUG Bexarotene

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center of University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2004-01
Phase Phase 1

Sponsor

Abramson Cancer Center at Penn Medicine

402 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00316030

The ClinicalTrials.gov registry entry for NCT00316030 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (53% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Bexarotene is the first listed.

NCT00316030 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00316030 about?

NCT00316030 is a clinical study titled "Study of Bexarotene in Patients With Acute Myeloid Leukemia". Bexarotene may be useful in the treatment of Acute Myeloid Leukemia (AML). This is the first study on the use of bexarotene to treat patients with AML. The main purpose of this study is to establish the proper dose of bexarotene when used to treat AML. The side effect profile of bexarotene in patien...

What is the current status of trial NCT00316030?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2004-01.

What conditions does trial NCT00316030 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, AML.

What interventions are being tested in trial NCT00316030?

The interventions under investigation include: Bexarotene (DRUG).

Who is sponsoring clinical trial NCT00316030?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00316030 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

AML

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.